A phase I study of Affinity-tuned ICAM-1 specific CAR T against advanced thyroid cancer patients
A Talk by Moonsoo M. Jin (Director, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, NY, USA)
Proudly supported by
About this Talk
We developed ICAM-1 targeting CAR T cells through a systematic approach to affinity-tune CAR for T cells to be selective to tumors with overexpressed ICAM-1 yet to spare normal cells with basal expression of ICAM-1. Our CAR vector has SSTR2 as a genetic reporter that allows PET/CT monitoring of CAR T distribution in patients, which we use to monitoring CAR T activity at tumor and off-tumor sites. While monitoring safety of our CAR T cells in patients with advanced thyroid cancer by blood markers and PET/CT images, we also analyze peripheral blood to look for cell-free tumor DNA, cytokines, single cell analysis of T cells, and the presence of CAR T cells by ddPCR.